Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $8.46 and traded as high as $8.94. Alpine Immune Sciences shares last traded at $8.80, with a volume of 60,111 shares changing hands. Analyst Upgrades and […]
- Just – Evotec Biologics will apply its fully integrated technology platform to develop an optimized commercial process for ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus... | August 10, 2022
10.08.2022 - DGAP-News: Evotec SE / Key word(s): Miscellaneous Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303 10.08.2022 / 07:30 The issuer is solely responsible for the content of this ... Seite 1
(RTTNews) - Evotec AG (EVO), a German life science company, Wednesday said its US-based subsidiary, Just - Evotec Biologics, Inc., expanded a mult...
19.07.2022 - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of Jörn Drappa, MD, PhD, to ... Seite 1